No abstract

in Wiley Online Library (wileyonlinelibrary.com).N 0 ,N″- ([1,-4,4 0 -diyl)bis(2-oxopropanehydrazonoyl chloride) is considered to be the key intermediate for the synthesis of a variety bis-1,3,4-thiadiazole derivatives in one step methodology with good yields by reaction of with a series of hydrazinecarbodithioate derivatives 2a-e, 6a,b, and 8a-e. The assigned structures for all the newly synthesized compounds were confirmed on the basis of elemental analyses and spectral data (infrared, NMR, and mass), and the mechanisms of their formation were also discussed. Moreover, the antimicrobial activity for twelve selected products was screened, and the results obtained exploring the high potency of some of the tested compounds compared with the employed standard bactericides and fungicides. In addition, the minimum inhibitory concentration of the tested compounds was determined, and the results obtained exploring the high potency of three of the tested compounds against all the tested microorganisms.

No abstract

Copper (II), palladium(II) and zinc(II) complexes of phosphonate derivative (S)-2-((phenoxyphosphono)(2-hydroxyphenyl) methyl-amino)-4-carbamoylbutanoic acid (PHCB) have been prepared and fully characterized by IR, elemental analysis, UV/Vis, 1 H-NMR, thermal analysis and Transmission Electron Microscope (TEM). The IR spectral data showed that the metal is coordinated to PHCB through carboxylic and NH groups. Carboxylic group behaves as a bidentate ligand with displacement of the proton, at the same time the metal coordinate with nitrogen atom of NH with the proton displacement. The complexes structure was supported by 1 H-NMR which shows the disappearance of both carboxylic and NH protons. The metal complexes stability was studied by thermal analysis. The activity of the organic ligands and their metal complexes as anticancer agents towards Hepatocellular carcinoma have been investigated. Zinc complex Zn(II)PHCB showed the highest activity with IC 50 = 9.58 µg/ml suggesting a promising anticancer drug in the future.